Biostax Corp. is a biopharmaceutical company which acquires and develops immune restoration pharmaceutical and medical technology products with a well -defined path to market. Biostax Corp., formerly known as Immune Therapeutics Inc., is based in Orlando, FL.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-1.65M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -599.83% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.00 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.00 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.05 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.01 |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 86.32M |
| Free Float | 76.22M |
| Market Capitalization | $0.02M |
| Average Volume (Last 20 Days) | 5.60 |
| Beta (Past 60 Months) | 0.82 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 11.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |